2020
A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
Khan S, Zhao F, Solin L, Goldstein L, Cella D, Basik M, Golshan M, Julian T, Pockaj B, Lee C, Razaq W, Sparano J, Babiera G, Dy I, Jain S, Silverman P, Fisher C, Tevaarwerk A, Wagner L, Sledge G. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Journal Of Clinical Oncology 2020, 38: lba2-lba2. DOI: 10.1200/jco.2020.38.18_suppl.lba2.Peer-Reviewed Original ResearchOptimal systemic therapyIntact primary tumorEarly local therapyLocoregional treatmentRecurrence/progressionOverall survivalSystemic therapyLocal therapyBreast cancerDe novo stage IV breast cancerDe novo metastatic breast cancerFACT-B Trial Outcome IndexNovo metastatic breast cancerRandomized phase III trialStage IV breast cancerCox proportional hazards modelInitial systemic therapyLocal disease progressionLocoregional disease controlMonths post randomizationYear OS ratesStage IV diseaseStage IV patientsPhase 3 trialPhase III trials
2015
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?
Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? European Journal Of Surgical Oncology 2015, 41: 1288-1292. PMID: 26238477, DOI: 10.1016/j.ejso.2015.07.013.Peer-Reviewed Original ResearchConceptsDe novo metastatic breast cancerNovo metastatic breast cancerMetastatic breast cancerBreast cancer patientsBreast cancerSurvival benefitCancer patientsPrimary tumorRetrospective non-randomized clinical studyDe novo metastatic diseasePrimary metastatic breast cancerNon-randomized clinical studyTumor-related symptomsPrimary tumor excisionSelection of patientsWound issuesBiologic therapyMetastatic diseaseSystemic therapyDistant metastasisEpidemiological burdenInitial diagnosisSurgical excisionPatient preferencesTumor excision